COVID-19, Death, Assisted, Infections, Morality
Conditions
Brief summary
In the assessment of severity in coronavirus disease 2019 (COVID-19), the modified Brit\_x0002\_ish Thoracic Society (mBTS)，CURB65 et al. rules identifies patients with severe pneumonia but not patients who might be suitable for home management. A multicentre prospective study was conducted to derive and validate a practical severity assessment model for stratifying adults hospitalised with COVID-19 into different management groups.
Detailed description
1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 30-day evaluation period: 4. Completion of baseline procedures Participants were assessed for 30 days and completed all safety monitoring.
Interventions
DIAGNOSTIC_TESTMedical observation
Likely suitable for home treatment
DIAGNOSTIC_TESTSupportive treatment (BSC)
Consider hospital supervised treatment
DIAGNOSTIC_TESTIntensive care management
Manage in hospital as severe pneumonia
Sponsors
Fuzhou General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with novel coronavirus infection meeting the criteria of The New Coronavirus Pneumonia Diagnosis and Treatment Program (Ninth Edition); 2. Participants are willing to participate in this study and follow the research plan; 3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website.
Exclusion criteria
1. pneumonia was (a) not the primary cause for hospital admission, (b) an expected terminal event,or (c) distal to bronchial obstruction; 2. patients with tuberculosis,bronchiectasis,solid organ and haematological malignancies or human immuno deficiency virus (HIV) infection; 3. patients who had been in hospital within the previous 14days, were immunocompromised,or had previously been entered in the study; 4. nursing home residents.Participation in other clinical study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30days | Mortality within 30days after diagnosis; Death from any cause |
| Deterioration of the condition | Day 1 to 30 days | Deterioration of the condition: refer to Guidelines for the Diagnosis and Treatment of Novel Coronavirus Infection by the National Health Commission (Trial Version 9) The development from asymptomatic to mild/general-type. The development from mild to general-type/severe type The development from general-type to severe/critical type The development from severe to critical type |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to sustained disappearance of clinical symptoms | Up to 30 days | Time to sustained disappearance of clinical symptoms |
| Percentage of participants with no clinical symptom | Day 3, 5, 7, 10, 14, 21 and 28 | Percentage of participants with no clinical symptoms from baseline to Day 3, 5, 7, 10, 14, 21 and 28 |
| Percentage of participants who turned negative for SARS-CoV-2 and/or COVID-19 antigen | Day 3, 5, 7, 10, 14, 28 | Percentage of participants who turned negative for SARS-COV-2 COVID-19 antigen at Day 3, 5, 7, 10, 14, 28 |
| Safety assessment Results: such as AEs and SAEs through Day 30 | Up to 30 days | Safety assessment Results: such as AEs and SAEs through Day 30 |
Countries
China
Contacts
Primary Contactzongyang yu, Ph.D
Backup Contactjinhe xu, doctor
Outcome results
None listed